Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity and type 2 diabetes
2022-002235-60Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and type 2 diabetes mellitus (T2DM) comparing Semaglutide 7.2 mg once weekly with Placebo once weekly (2 arms). Primary endpoint: Relative change in body weight. Started Oct 2022; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-002235-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002235-60.